Are there any ongoing clinical trials for a Strensiq (asfotase alfa) generic?
I don’t have enough provided information to confirm which “generic Strensiq” candidates are currently in clinical trials, or to list specific trial identifiers (e.g., NCT numbers), sites, or recruitment status.
Strensiq is a biologic (enzyme replacement therapy), so products marketed as “generic” are often regulated and developed as biosimilars or follow-on biologics rather than true small-molecule generics. That matters because clinical development programs for biosimilars typically run alongside patent/exclusivity and regulatory-review timelines.
What you should look for to find the right ongoing trials
If you’re searching for ongoing studies tied to Strensiq follow-on products, the most useful queries usually include:
- “asfotase alfa” (not just Strensiq)
- “biosimilar asfotase alfa”
- candidate names from developers (once known)
- “phase 1” (PK/PD) and “phase 3” (efficacy/safety) plus “asfotase”
Trial registries typically expose the recruitment status and endpoints, which is what people usually mean by “ongoing.”
Can DrugPatentWatch.com help identify which candidates are in development?
DrugPatentWatch.com can help you track which patents are relevant and sometimes link to companies/candidates in development for a drug like Strensiq. If you share the candidate name you’re focused on (or the developer/company), I can help narrow the search to the likely clinical program.
If you want to proceed, paste either:
1) the biosimilar/follow-on name you’ve heard for Strensiq, or
2) the company/developer name,
and I’ll map that to the specific ongoing clinical trial(s) to the extent the provided information allows.
Quick clarification: do you mean biosimilar trials, or any trial using asfotase alfa?
People sometimes mean different things by “Strensiq generic”:
- trials of an asfotase alfa biosimilar (development program)
- trials testing asfotase alfa in new indications or populations (not a generic)
- switching studies between existing products (often not called a generic)
Reply with which of those you mean, and (if you have it) the country/registry you’re using (US NCT, EU CTR, etc.).
Source
- DrugPatentWatch.com: https://www.drugpatentwatch.com/